

Study Summary




A Multi-national Phase 3 Study

Canakinumab ANti-inflammatory Thrombosis Outcomes Study

A *Canakinumab Outcomes Study* funded by Novartis who manufacture the drug.

This trial tested whether reducing inflammation among men and women who have had a prior heart attack can reduce the risk of another or a stroke happening in the future.



CANTOS was a **double-blind randomised, placebo-controlled trial** in 10,072 patients who had previously had a heart attack and had evidence of systemic inflammation.

The results flowing from this study have far reaching effects and have led to further studies being planned, including investigation into the effects in cancer."

"CANTOS has definitively proven that targeted anti-inflammatory therapy – at least with interleukin-1b inhibition – can significantly lower rates of heart attack and cardiovascular death in the absence of any effects on lipids or blood pressure."

Prof Paul Ridker, Professor of Medicine, Harvard Medical School